268 related articles for article (PubMed ID: 28480764)
1. Novel agents in mantle cell lymphoma.
Tucker D; Rule S
Expert Rev Anticancer Ther; 2017 Jun; 17(6):491-506. PubMed ID: 28480764
[TBL] [Abstract][Full Text] [Related]
2. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
Nastoupil LJ; Koff JL; Flowers CR
Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
[TBL] [Abstract][Full Text] [Related]
3. Does maintenance therapy have a role in mantle cell lymphoma treatment?
Parrott M; Rule S
Expert Rev Hematol; 2018 Apr; 11(4):285-292. PubMed ID: 29521148
[TBL] [Abstract][Full Text] [Related]
4. [Current therapeutic strategies for mantle cell lymphoma].
Dreyling M; Schnaiter A; Schmidt C; Hoster E
Internist (Berl); 2016 Mar; 57(3):230-7. PubMed ID: 26886710
[TBL] [Abstract][Full Text] [Related]
5. Novel therapies for relapsed/refractory mantle cell lymphoma.
Arora PC; Portell CA
Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
[TBL] [Abstract][Full Text] [Related]
6. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Arkwright R; Pham TM; Zonder JA; Dou QP
Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
[TBL] [Abstract][Full Text] [Related]
7. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
Papin A; Le Gouill S; Chiron D
Leuk Lymphoma; 2018 May; 59(5):1064-1072. PubMed ID: 28758825
[TBL] [Abstract][Full Text] [Related]
8. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
[TBL] [Abstract][Full Text] [Related]
9. Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?
El Halabi L; Ghez D; Ribrag V
Expert Rev Hematol; 2016 Mar; 9(3):271-81. PubMed ID: 26689790
[TBL] [Abstract][Full Text] [Related]
10. Treatment options for mantle cell lymphoma.
Smolewski P; Witkowska M; Robak T
Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
12. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
13. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).
Stefoni V; Pellegrini C; Broccoli A; Baldini L; Tani M; Cencini E; Figuera A; Ansuinelli M; Bernocco E; Cantonetti M; Cox MC; Ballerini F; Rusconi C; Visco C; Arcaini L; Fama A; Marasca R; Volpetti S; Castellino A; Califano C; Cavaliere M; Gini G; Liberati AM; Musuraca G; Lucania A; Ricciuti G; Argnani L; Zinzani PL
Oncologist; 2018 Sep; 23(9):1033-1038. PubMed ID: 29674440
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide for the treatment of mantle cell lymphoma.
Morabito F; Skafi M; Recchia AG; Kashkeesh A; Hindiyeh M; Sabatleen A; Morabito L; Alijanazreh H; Hamamreh Y; Gentile M
Expert Opin Pharmacother; 2019 Apr; 20(5):487-494. PubMed ID: 30608891
[TBL] [Abstract][Full Text] [Related]
17. Mantle cell lymphoma in relapse: the role of emerging new drugs.
Diefenbach CS; O'Connor OA
Curr Opin Oncol; 2010 Sep; 22(5):419-23. PubMed ID: 20679769
[TBL] [Abstract][Full Text] [Related]
18. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.
Klener P
Expert Opin Ther Targets; 2020 Oct; 24(10):1029-1045. PubMed ID: 32842810
[TBL] [Abstract][Full Text] [Related]
19. Mantle cell lymphoma-management in evolution.
Rajguru S; Kahl BS
Chin Clin Oncol; 2015 Mar; 4(1):8. PubMed ID: 25841715
[TBL] [Abstract][Full Text] [Related]
20. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.
Dreyling M; Aurer I; Cortelazzo S; Hermine O; Hess G; Jerkeman M; Le Gouill S; Ribrag V; Trněný M; Visco C; Walewski J; Zaja F; Zinzani PL
Leuk Lymphoma; 2018 Aug; 59(8):1814-1828. PubMed ID: 29172868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
